Skip to content
Cultural Foundation
Author:
Caris Life Sciences
Caris Life Sciences, ECOG-ACRIN and NRG Oncology Study Demonstrates Multimodal AI Approach to Predict Late Distant Recurrence Risk in HR+ Early Breast Cancer
August 6, 2026
Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
August 5, 2026
Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026
July 16, 2026
Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
July 14, 2026
Caris Life Sciences Launches Caris Detect, the World’s Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test
July 1, 2026
Caris Life Sciences Announces Dual Listing on NYSE Texas
June 16, 2026
Caris Life Sciences Announces Share Repurchase Program
June 8, 2026